ValiRx plc (VAL) - Cash Flow Conversion Efficiency

Latest as of December 2024: -0.179x

Based on the latest financial reports, ValiRx plc (VAL) has a cash flow conversion efficiency ratio of -0.179x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£-700.73K ≈ $-941.02K USD) by net assets (£3.92 Million ≈ $5.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ValiRx plc (VAL) defensive interval to measure how many days the company can operate on defensive assets alone.

ValiRx plc - Cash Flow Conversion Efficiency Trend (2001–2024)

This chart illustrates how ValiRx plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

ValiRx plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ValiRx plc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
TTL Beteiligungs- und Grundbesitz-AG F:TTO	0.226x
STL Global Limited NSE:SGL	-0.005x
Devernois SA PA:ALDEV	0.100x
Glacier Lake Resources Inc V:GLI	0.010x
Zonetail Inc V:ZONE	0.041x
Commander Resources Ltd V:CMD	-0.123x
VCI Global Limited Ordinary Share NASDAQ:VCIG	0.154x
Copper Lake Resources Ltd V:CPL	-0.058x

Annual Cash Flow Conversion Efficiency for ValiRx plc (2001–2024)

The table below shows the annual cash flow conversion efficiency of ValiRx plc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see ValiRx plc (VAL) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	£3.92 Million ≈ $5.26 Million	£-1.58 Million ≈ $-2.13 Million	-0.405x	+33.68%
2023-12-31	£2.90 Million ≈ $3.90 Million	£-1.77 Million ≈ $-2.38 Million	-0.610x	-36.39%
2022-12-31	£3.83 Million ≈ $5.14 Million	£-1.71 Million ≈ $-2.30 Million	-0.447x	-21.21%
2021-12-31	£3.41 Million ≈ $4.59 Million	£-1.26 Million ≈ $-1.69 Million	-0.369x	+8.12%
2020-12-31	£4.76 Million ≈ $6.39 Million	£-1.91 Million ≈ $-2.57 Million	-0.402x	+33.42%
2019-12-31	£2.22 Million ≈ $2.99 Million	£-1.34 Million ≈ $-1.80 Million	-0.604x	+45.45%
2018-12-31	£3.03 Million ≈ $4.07 Million	£-3.35 Million ≈ $-4.50 Million	-1.106x	-48.34%
2017-12-31	£3.15 Million ≈ $4.23 Million	£-2.35 Million ≈ $-3.16 Million	-0.746x	+58.08%
2016-12-31	£2.37 Million ≈ $3.18 Million	£-4.22 Million ≈ $-5.66 Million	-1.779x	-211.40%
2015-12-31	£4.53 Million ≈ $6.09 Million	£-2.59 Million ≈ $-3.48 Million	-0.571x	+47.02%
2014-12-31	£2.79 Million ≈ $3.74 Million	£-3.01 Million ≈ $-4.04 Million	-1.079x	-68.52%
2013-12-31	£3.23 Million ≈ $4.34 Million	£-2.07 Million ≈ $-2.78 Million	-0.640x	-62.79%
2012-12-31	£5.04 Million ≈ $6.76 Million	£-1.98 Million ≈ $-2.66 Million	-0.393x	-19.06%
2011-12-31	£4.42 Million ≈ $5.94 Million	£-1.46 Million ≈ $-1.96 Million	-0.330x	-32.96%
2010-12-31	£2.00 Million ≈ $2.68 Million	£-496.00K ≈ $-666.08K	-0.248x	+75.67%
2009-12-31	£907.00K ≈ $1.22 Million	£-926.00K ≈ $-1.24 Million	-1.021x	-76.42%
2008-12-31	£1.37 Million ≈ $1.84 Million	£-794.00K ≈ $-1.07 Million	-0.579x	-15.19%
2007-12-31	£1.67 Million ≈ $2.24 Million	£-839.00K ≈ $-1.13 Million	-0.502x	-2848.55%
2006-12-31	£2.69 Million ≈ $3.61 Million	£-45.77K ≈ $-61.46K	-0.017x	+95.01%
2006-03-31	£161.00K ≈ $216.21K	£-55.00K ≈ $-73.86K	-0.342x	-210.08%
2005-12-31	£-203.00K ≈ $-272.61K	£-63.00K ≈ $-84.60K	0.310x	-90.48%
2004-12-31	£-69.00K ≈ $-92.66K	£-225.00K ≈ $-302.15K	3.261x	+195.24%
2003-12-31	£67.00K ≈ $89.97K	£74.00K ≈ $99.38K	1.104x	+108.81%
2002-12-31	£-141.00K ≈ $-189.35K	£1.77 Million ≈ $2.37 Million	-12.539x	-759.53%
2001-12-31	£1.00 Million ≈ $1.35 Million	£1.91 Million ≈ $2.56 Million	1.901x	--

About ValiRx plc

LSE:VAL UK Biotechnology

Market Cap

$184.52 Million

£137.40 Million GBP

Market Cap Rank

#29436 Global

#581 in UK

Share Price

£0.19

Change (1 day)

+0.00%

52-Week Range

£0.18 - £0.75

All Time High

£3312.50